2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0180C
    Imiquimod dihydrochloride
    		Inhibitor
    Imiquimod (R 837) dihydrochloride, an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.
    Imiquimod dihydrochloride
  • HY-163738
    Furin-IN-2
    		Inhibitor
    Furin-IN-2 (compound P3) is a potent inhibitor of furin, with the IC50 of 35 μM. Furin-IN-2 shows antiviral activity.
    Furin-IN-2
  • HY-B0879AR
    Suramin sodium salt (Standard)
    		Inhibitor
    Suramin (sodium salt) (Standard) is the analytical standard of Suramin (sodium salt). This product is intended for research and analytical applications. Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.
    Suramin sodium salt (Standard)
  • HY-163713
    SARS-CoV-2-IN-89
    		Inhibitor
    SARS-CoV-2-IN-89 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells.
    SARS-CoV-2-IN-89
  • HY-12530R
    Velpatasvir (Standard)
    		Inhibitor
    Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.
    Velpatasvir (Standard)
  • HY-161777
    SARS-CoV-2 Mpro-IN-23
    		Inhibitor
    SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC50 of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC50 of 0.02-0.52 μM.
    SARS-CoV-2 Mpro-IN-23
  • HY-B0462A
    Azelastine
    		Inhibitor
    Azelastine, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.
    Azelastine
  • HY-171189
    C-467929
    		Inhibitor
    C-467929 is an Nsp15 endoribonuclease inhibitor with an IC50 of 8 μM. C-467929 binds to the SARS-CoV Nsp15 protein and can be utilized in infection research.
    C-467929
  • HY-177332
    SLC-391
    		Inhibitor
    SLC-391 is a selective, orally active AXL inhibitor with an IC50 of 9.6 nM. SLC-391 has antiviral activity.
    SLC-391
  • HY-157539
    PB49673382
    		Inhibitor
    PB49673382 is a SARS-CoV-2 inhibitor. PB49673382 inhibits virus replication and consequent cytopathic effects of the virus with an IC50 of 6.42 μM.
    PB49673382
  • HY-157305
    Jun11165
    		Inhibitor
    Jun11165 is a SARS-CoV-2 PLpro inhibitor (IC50 ≤ 0.6 μM), which inhibits SARS-CoV-2 with an EC50 value of ≤ 6 μM. Jun11165 can be used in the research of viral infections.
    Jun11165
  • HY-111074
    DB12055
    		Inhibitor
    DB12055 (MK-0767 analog) is a covalent SARS-CoV-2 3CL protease inhibitor. DB12055 has the potential for the study of dyslipidemia and diabetes mellitus.
    DB12055
  • HY-159932
    SARS-CoV-2 Mpro-IN-30
    		Inhibitor
    SARS-CoV-2 Mpro-IN-30 (compound L2) is a SARS-CoV-2 Mpro with the IC50 of 9.1 nM.
    SARS-CoV-2 Mpro-IN-30
  • HY-163029
    CTSL/B-IN-1
    		Inhibitor
    CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC50s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research.
    CTSL/B-IN-1
  • HY-172027
    Remdesivir methylpropyl ester analog
    Remdesivir methylpropyl ester analog (GS-5734 methylpropyl ester analog) is a derivative of Remdesivir (HY-104077). Remdesivir is a nucleoside analogue with effective antiviral activity.
    Remdesivir methylpropyl ester analog
  • HY-12594R
    Paritaprevir (Standard)
    		Inhibitor
    Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor).
    Paritaprevir (Standard)
  • HY-136597R
    Remdesivir O-desphosphate acetonide impurity (Standard)
    		Inhibitor
    Remdesivir O-desphosphate acetonide impurity (Standard) is the analytical standard of Remdesivir O-desphosphate acetonide impurity. This product is intended for research and analytical applications.
    Remdesivir O-desphosphate acetonide impurity (Standard)
  • HY-155601
    SARS-CoV-2-IN-52
    		Inhibitor
    SARS-CoV-2-IN-52 (Compound 5) is an inhibitor for SARS-CoV-2 with a pIC50 of 0.3187.
    SARS-CoV-2-IN-52
  • HY-108325S
    Brequinar-d3
    		Inhibitor
    Brequinar-d3 (DUP785-d3) is deuterium labeled Brequinar. Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity.
    Brequinar-d<sub>3</sub>
  • HY-161070
    Antiviral agent 46
    		Inhibitor
    Antiviral agent 46 (compound 4) is a derivative of cannabidiol (CBD) with anti-SARS-CoV-2 (IC50: 1.90 μM) and ACE2 activity (IC50: 1.37 μM).
    Antiviral agent 46
Cat. No. Product Name / Synonyms Species Source